You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Natural product and natural product derived drugs in clinical trials
|
|---|---|
| Published in |
Natural Product Reports, January 2014
|
| DOI | 10.1039/c4np00064a |
| Pubmed ID | |
| Authors |
Mark S. Butler, Avril A. B. Robertson, Matthew A. Cooper |
| Abstract |
There are a significant number of natural product (NP) drugs in development. We review the 100 NP and NP-derived compounds and 33 Antibody Drug Conjugates (ADCs) with a NP-derived cytotoxic component being evaluated in clinical trials or in registration at the end of 2013. 38 of these compounds and 33 ADCs are being investigated as potential oncology treatments, 26 as anti-infectives, 19 for the treatment of cardiovascular and metabolic diseases, 11 for inflammatory and related diseases and 6 for neurology. There was a spread of the NP and NP-derived compounds through the different development phases (17 in phase I, 52 in phase II, 23 in phase III and 8 NDA and/or MAA filed), while there were 23 ADCs in phase I and 10 in phase II. 50 of these 100 compounds were either NPs or semi-synthetic (SS) NPs, which indicated the original NP still plays an important role. NP and NP-derived compounds for which clinical trials have been halted or discontinued since 2008 are listed in the Supplementary Information. The 25 NP and NP-derived drugs launched since 2008 are also reviewed, and late stage development candidates and new NP drug pharmacophores analysed. The short term prospect for new NP and NP-derived drug approvals is bright, with 31 compounds in phase III or in registration, which should ensure a steady stream of approvals for at least the next five years. However, there could be future issues for new drug types as only five new drug pharmacophores discovered in the last 15 years are currently being evaluated in clinical trials. The next few years will be critical for NP-driven lead discovery, and a concerted effort is required to identify new biologically active pharmacophores and to progress these and existing compounds through pre-clinical drug development into clinical trials. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 573 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 3 | <1% |
| Brazil | 3 | <1% |
| Ireland | 1 | <1% |
| Chile | 1 | <1% |
| Australia | 1 | <1% |
| Sweden | 1 | <1% |
| Switzerland | 1 | <1% |
| United Kingdom | 1 | <1% |
| Canada | 1 | <1% |
| Other | 6 | 1% |
| Unknown | 554 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 121 | 21% |
| Researcher | 73 | 13% |
| Student > Master | 72 | 13% |
| Student > Bachelor | 46 | 8% |
| Student > Postgraduate | 28 | 5% |
| Other | 122 | 21% |
| Unknown | 111 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 156 | 27% |
| Agricultural and Biological Sciences | 87 | 15% |
| Biochemistry, Genetics and Molecular Biology | 83 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 32 | 6% |
| Medicine and Dentistry | 22 | 4% |
| Other | 55 | 10% |
| Unknown | 138 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 July 2023.
All research outputs
#4,738,020
of 23,524,722 outputs
Outputs from Natural Product Reports
#285
of 1,132 outputs
Outputs of similar age
#55,441
of 308,923 outputs
Outputs of similar age from Natural Product Reports
#12
of 43 outputs
Altmetric has tracked 23,524,722 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,132 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 308,923 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.